Myles A B
Rheumatol Rehabil. 1975 Nov;14(4):231-5. doi: 10.1093/rheumatology/14.4.231.
The seven-year results of all cases (84) diagnosed as polymyalgia rheumatica or giant cell arteritis are reported. The diagnosis proved to be incorrect in seven, of which six had a polyarthritis. Most cases were treated with prednisolone, starting with 20 mg daily for those with evidence of cranial arteritis, and 10 mg for those without. Fourteen patients were withdrawn from treatment (after three months to 31/2 years--mean 21 months), but three relapsed and treatment has been restarted. There was no correlation between the presence or absence of arteritis, the starting dose of prednisolone and the subsequent duration of treatment. A small group (7) received higher doses without obvious advantage. Twenty-two started on 5-9 mg daily, but the dose had to be increased in 13 because of inadequate control of symptoms. Objective physical abnormality, particularly painful limitation of shoulder movement, was present in most cases. No patient developed a serious complication of the disease after treatment had been started. Complications of treatment were infrequent. Spinal osteoporosis occurred in seven, but did not cause long-term disability.
报告了84例被诊断为风湿性多肌痛或巨细胞动脉炎的所有病例的七年随访结果。结果发现7例诊断有误,其中6例患有多关节炎。大多数病例接受泼尼松龙治疗,有颅动脉炎证据的患者起始剂量为每日20mg,无颅动脉炎证据的患者起始剂量为10mg。14例患者停止治疗(时间从3个月至3年半,平均21个月),但3例复发,随后重新开始治疗。动脉炎的有无、泼尼松龙的起始剂量与后续治疗持续时间之间无相关性。一小部分患者(7例)接受了更高剂量的治疗,但并无明显益处。22例患者起始剂量为每日5 - 9mg,但其中13例因症状控制不佳而不得不增加剂量。大多数病例存在客观的身体异常,尤其是肩部运动疼痛受限。开始治疗后,没有患者出现该疾病的严重并发症。治疗并发症并不常见。7例出现脊柱骨质疏松,但未导致长期残疾。